PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UK approval for Epidyolex to treat seizures from tuberous sclerosis

Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients aged two years and older.

The developer of cannabis-based medicines was initially granted marketing authorisation for Epidyolex in the UK in September 2019 as adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients aged two years and older. GW also received a positive NICE recommendation for the medicine in this indication.

The TSC authorisation is the fourth approved indication of cannabis-based medicine in the UK for GW, the company said in a statement.

Commenting on the MHRA approval of Epidyolex, Tuberous Sclerosis Association (TSA) chief executive Louise Fish said: “One in every two people living with TSC-related epileptic seizures has difficult to treat epilepsy that does not respond to traditional anti-epileptic drugs.  We are excited to see this new medicine approved by the MHRA, which gives people living with TSC and their families hope. We desperately need further options for clinicians who are managing seizures associated with TSC, and we, therefore, welcome this decision by the MHRA.”

The approval is based on data from a positive Phase III study, which showed a reduction in seizure frequency compared to baseline of Epidyolex vs placebo, with seizure reduction of 49% in patients taking Epidyolex 25 mg/kg/day compared with 27% for placebo.

The approval follows the recent approval of the product in all 27 countries of the European Union, alongside Norway, Iceland and Liechtenstein (including Northern Ireland).

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026